Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
Screening and treatment for prostate cancer is controversial. In the absence of randomized trials, several prominent medical organizations in the United States and Europe have formulated policies that range from enthusiastic support to significant skepticism concerning the efficacy of screening and subsequent treatment for prostate cancer. Sharp rises in the incidence of prostate cancer have occurred whenever PSA testing has been introduced on a wide scale. Unfortunately, it is unclear whether declines in prostate cancer mortality can be attributed to PSA testing. Other explanations include the early use of anti-androgen therapy or changes in environmental factors such as diet. Repeated testing for serum PSA has produced significant shifts in the types of cases being identified and has raised the possibility of significant over-diagnosis of this disease. The European screening trial and the PLCO trial in the US will hopefully provide some insights into the value of population-based testing.
Albertsen
Peter C
PC
Department of Surgery, University of Connecticut Health Center, Farmington, 06030-3955, USA. Albertsen@nso.uchc.edu
D005060:Europe; D006291:Health Policy; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D011159:Population Surveillance; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D011634:Public Health; D016896:Treatment Outcome; D014481:United States
D017430:Prostate-Specific Antigen